Drug Profile
TCT 370
Alternative Names: TCT-370Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Targeted Cell Therapies
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Gaucher's disease type I
Highest Development Phases
- No development reported Gaucher's disease type I
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Gaucher's disease type I in USA (PO)
- 13 Jul 2016 TCT 370 is available for licensing as of 13 Jul 2016. http://www.targetedcelltherapies.us/
- 13 Jul 2016 Preclinical trials in Gaucher's disease type I in USA (PO)